Bluefish Pharmaceuticals
Prachi Rathore is an experienced professional in supply chain management and operations within the pharmaceutical industry. Currently serving as the Head of Supply Chain Management - Global Operations at Bluefish Pharmaceuticals since March 2021, Prachi has previously held significant roles including Head of CMO Operations at Biocon and Head of SCM-CMO at Strides Shasun Limited. Prachi's career also includes leadership positions such as Vice President Operations at Synokem Pharmaceuticals Ltd and V.P. Operations at Affy Pharma Pvt Ltd, where responsibilities encompassed contract manufacturing, business development, and regulatory compliance. Educational qualifications include a Master in Chemical Sales and Marketing Management from the Indian Institute of Management, Calcutta, and a Bachelor of Applied Science in Environmental Science from Jiwaji University, complemented by a certificate in Bioinformatics from Bio-Info Inc, USA.
This person is not in the org chart
This person is not in any offices
Bluefish Pharmaceuticals
Founded in Sweden, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals has become one of the most progressive generics pharmaceuticals companies. At Bluefish, we strive to make quality medicines accessible to more people. We create value in the full pharmaceutical value chain from developing to manufacturing and successfully marketing generic pharmaceuticals and we take pride in doing this in an innovative, responsible and cost-efficient way. Bluefish currently conducts operations in 19 countries in Europe and, over the next few years, will also expand outside Europe with the aim of becoming a global player. Our corporate culture and close collaboration with development and manufacturing partners are integral parts of our effort to deliver quality products at affordable prices. We offer a product portfolio consisting of a broad range of high quality generics for all major therapeutic areas. It is part of our long-term strategy to expand the product portfolio of off-patent blockbusters while at the same time offering a broader range of niche products within more narrow disease areas.